News

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...
Adaptive clinical trial design represents a modern approach to evaluating healthcare interventions that allows pre‐specified modifications based on accumulating data. This flexible methodology ...
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...
Artificial Intelligence (AI) is no longer just a buzzword it is transforming the way healthcare is delivered and its influence is now reaching deep into the world of clinical trials from predicting ...
How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical ...
With artificial intelligence (AI) fast becoming an ubiquitous part of everyday life, its further application in clinical ...
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts ...
The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...
With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.